RGCNasdaqMedicinal Chemicals & Botanical Products
Regencell Bioscience Holdings Ltd
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026
$10.05+0.46 (+4.80%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Regencell Bioscience Holdings Ltd revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Regencell Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.